{"ticker": {"uuid": "68968c7d-40fa-4e2e-a6be-6c57dd40fc8d", "symbol": "RLAY", "name": "Relay Therapeutics\u00a0Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Canaccord initiates Relay Therapeutics stock with buy rating", "summary": "Canaccord has initiated coverage on Relay Therapeutics Inc. (NASDAQ:RLAY) with a buy rating and a price target of $29.00, citing its lead asset zovegalisib. The firm believes zovegalisib, targeting mutant PI3K\u03b1, offers improved efficacy and safety for breast cancer and vascular a", "url": "https://www.investing.com/news/analyst-ratings/canaccord-initiates-relay-therapeutics-stock-with-buy-rating-93CH-4796138", "source_name": "Investing.com", "published_at": "2026-07-16T14:11:07", "published_display": "16 Jul 2026 14:11", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Canaccord Genuity Initiates Relay Therapeutics at Buy With $29 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/canaccord-genuity-initiates-relay-therapeutics-113810107.html", "source_name": "MT Newswires", "published_at": "2026-07-16T11:38:10+00:00", "published_display": "16 Jul 2026 11:38", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CCORF Initiates Relay Therapeutics(RLAY.US) With Buy Rating, Announces Target Price $29", "summary": "CCORF has initiated coverage on Relay Therapeutics (RLAY.US) with a \"Buy\" rating. The firm has set a target price of $29 for the company's shares. This indicates a positive outlook on Relay Therapeutics' future performance by CCORF.", "url": "https://www.moomoo.com/news/post/73067634/ccorf-initiates-relay-therapeutics-rlayus-with-buy-rating-announces-target", "source_name": "Moomoo", "published_at": "2026-07-16T10:11:07", "published_display": "16 Jul 2026 10:11", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RLAY Stock Declines Pre-Market After $175M Offering \u2014 Despite Fresh Bullish Calls On Relay's Zovegalisib", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxNTTRWSldfYzZKOVR1LWFXbUl6YklEa0l5UmJlX2VhekVkV2hqQmxUR1VCNXBlZEV2QUIyYjRRQm9Gcy1tWUFMc1VhWFhHQXVmYWd3MTdSbWxOMGY3STZWQkpsdWhnejJKSURlR0R1MHJsQjV0Wmo3el9oWGZnMDM0LXN1T2lCdGR6Zl9WOUg3TnVaMWVHaGE3YnpOcmdXTmQ5WjJJTkhxcDdsX0thZF9SRko4NDlIcmtfU2pmUElIXzJYSVNyV2JyQmRIWWhJSEZMMjJCWA?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-14T15:18:41+00:00", "published_display": "14 Jul 2026 15:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Price to earnings forward of Relay Therapeutics, Inc. \u2013 NASDAQ:RLAY", "summary": "This article provides a financial overview of Relay Therapeutics, Inc. (NASDAQ: RLAY), focusing on its forward price-to-earnings ratio. It presents the company's financial data as available on TradingView, indicating that the market was closed at the time of publication with no t", "url": "https://www.tradingview.com/symbols/NASDAQ-RLAY/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T10:10:15", "published_display": "09 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics Insider Sold Shares Worth $331,131, According to a Recent SEC Filing", "summary": "A recent SEC filing revealed that Richard Peters, Chief Executive Officer of Relay Therapeutics, sold 30,000 shares of the company's common stock for a total of $331,131. The sale occurred at an average price of $11.0377 per share. Following this transaction, Peters still directl", "url": "https://www.moomoo.com/news/post/72670469/relay-therapeutics-insider-sold-shares-worth-331131-according-to-a", "source_name": "Moomoo", "published_at": "2026-07-09T02:10:57", "published_display": "09 Jul 2026 02:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell Alert: Donald Bergstrom Sells Shares of Relay Thera", "summary": "Donald Bergstrom, President of Research and Development at Relay Therapeutics Inc (RLAY), recently sold 8,660 company shares, reducing his holdings to 409,897 shares. This transaction is part of a trend over the last year where Bergstrom has sold 186,854 shares with no purchases,", "url": "https://www.gurufocus.com/news/8950625/insider-sell-alert-donald-bergstrom-sells-shares-of-relay-therapeutics-inc-rlay", "source_name": "GuruFocus", "published_at": "2026-07-09T01:10:57", "published_display": "09 Jul 2026 01:10", "sentiment": "negative", "sentiment_pct": 26, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics Insider Sold Shares Worth $943,736, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/relay-therapeutics-insider-sold-shares-211220901.html", "source_name": "MT Newswires", "published_at": "2026-07-08T21:12:20+00:00", "published_display": "08 Jul 2026 21:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics (RLAY) R&D chief sells 8,660 shares in 10b5-1 trade", "summary": "Donald A. Bergstrom, President of R&D at Relay Therapeutics (RLAY), sold 8,660 shares of common stock at a weighted average price of $18.71 per share under a pre-arranged Rule 10b5-1 trading plan. After the sale, Bergstrom still directly holds 409,897 shares, including restricted", "url": "https://www.stocktitan.net/sec-filings/RLAY/form-4-relay-therapeutics-inc-insider-trading-activity-c0d19af0a5f3.html", "source_name": "Stock Titan", "published_at": "2026-07-08T22:10:57", "published_display": "08 Jul 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics president and CEO Sanjiv Patel sells $943,736 in stock", "summary": "Sanjiv Patel, President and CEO of Relay Therapeutics (NASDAQ:RLAY), sold $943,736 worth of company stock on July 7, 2026, as part of a pre-arranged trading plan. This sale occurred while the stock was trading near its 52-week high, following a significant 450% gain over the past", "url": "https://www.investing.com/news/insider-trading-news/relay-therapeutics-president-and-ceo-sanjiv-patel-sells-943736-in-stock-93CH-4782624", "source_name": "Investing.com", "published_at": "2026-07-08T21:10:57", "published_display": "08 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics CFO Thomas Catinazzo sells $331,130 in stock", "summary": "Relay Therapeutics CFO Thomas Catinazzo sold 17,717 shares of the company's common stock for a total of $331,130 on July 6, 2026. The sale was executed via a Rule 10b5-1 trading plan and occurred while the stock (NASDAQ: RLAY) traded near its 52-week high after a significant gain", "url": "https://www.investing.com/news/insider-trading-news/relay-therapeutics-cfo-thomas-catinazzo-sells-331130-in-stock-93CH-4782587", "source_name": "Investing.com", "published_at": "2026-07-08T21:10:57", "published_display": "08 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics president sells $162,028 in company stock", "summary": "Donald A. Bergstrom, President, R&D at Relay Therapeutics (NASDAQ:RLAY), sold 8,660 shares of company stock for $162,028 on July 6, 2026, through a pre-arranged trading plan. This transaction occurred while Relay shares are near their 52-week high, following significant gains. De", "url": "https://www.investing.com/news/insider-trading-news/relay-therapeutics-president-sells-162028-in-company-stock-93CH-4782609", "source_name": "Investing.com", "published_at": "2026-07-08T21:10:57", "published_display": "08 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CFO at Relay Therapeutics (RLAY) sells shares under Rule 10b5-1 plan", "summary": "Relay Therapeutics CFO Thomas Catinazzo sold 17,717 shares of common stock on July 6, 2026, generating $331,131 at a weighted average price of $18.69 per share. These transactions were pre-arranged under a Rule 10b5-1 trading plan adopted in October 2025. Following the sale, Cati", "url": "https://www.stocktitan.net/sec-filings/RLAY/form-4-relay-therapeutics-inc-insider-trading-activity-5b084534580b.html", "source_name": "Stock Titan", "published_at": "2026-07-08T21:10:57", "published_display": "08 Jul 2026 21:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics (RLAY) CEO trades shares, keeps over 615K direct holdings", "summary": "Relay Therapeutics President and CEO Sanjiv Patel reported selling 48,199 shares of common stock at a weighted average price of $19.58 under a pre-established 10b5-1 trading plan. This transaction followed an acquisition of 3,056 shares through the company's Employee Stock Purcha", "url": "https://www.stocktitan.net/sec-filings/RLAY/form-4-relay-therapeutics-inc-insider-trading-activity-337e491872ee.html", "source_name": "Stock Titan", "published_at": "2026-07-08T21:10:57", "published_display": "08 Jul 2026 21:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Relay Therapeutics (RLAY) Is Up 5.5% After Broad Russell Growth Index Inclusion And What's Next", "summary": "Relay Therapeutics (RLAY) was included in multiple Russell Growth and Small Cap indices in late June 2026, boosting its visibility among institutional investors. While this inclusion may deepen liquidity and expand its shareholder base, it does not change the fundamental risks as", "url": "https://www.sahmcapital.com/news/content/why-relay-therapeutics-rlay-is-up-55-after-broad-russell-growth-index-inclusion-and-whats-next-2026-07-08", "source_name": "Sahm", "published_at": "2026-07-08T21:09:17", "published_display": "08 Jul 2026 21:09", "sentiment": "positive", "sentiment_pct": 60, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan initiates Relay Therapeutics stock coverage with overweight rating", "summary": "JPMorgan has initiated coverage on Relay Therapeutics Inc. (NASDAQ:RLAY) with an overweight rating and a $28 price target, citing its drug zovegalisib as a potential multi-indication growth driver with projected worldwide peak sales of approximately $8.3 billion. The stock, curre", "url": "https://www.investing.com/news/analyst-ratings/jpmorgan-initiates-relay-therapeutics-stock-coverage-with-overweight-rating-93CH-4780785", "source_name": "Investing.com", "published_at": "2026-07-08T08:09:31", "published_display": "08 Jul 2026 08:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 RELAY THERAPEUTICS INC For: 7 July By Investing.com", "summary": "This article announces the filing of Form 144 for RELAY THERAPEUTICS INC on July 7. The filing is a standard requirement for insiders wishing to sell restricted or control securities. This brief update is relevant for investors tracking insider transactions and regulatory filings", "url": "https://ca.investing.com/news/stock-market-news/form-144-relay-therapeutics-inc-for-7-july-93CH-4724062", "source_name": "Investing.com Canada", "published_at": "2026-07-07T21:41:45", "published_display": "07 Jul 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Relay Therapeutics, Inc. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPUXp1VXJOWnlmWmNxaFJkNHJ3U3RNR09kTHZrd0VGWk9oMDFhTWdIekp2S2Nlb3g0bGp5d29jeWZRVlpHQnE2MGo5bEVGUmJUcGNDemx3Nkg0LWY5dmtjSi1FZXljUXNZMUpPTWxjNXRPbU43UzNEb3V1aTViM2RSWFZNdWdmUFhpYlpWd2RXM0hGZzd1c3VuUWFCMDBzMGx3?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-07T20:37:03+00:00", "published_display": "07 Jul 2026 20:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics stock hits 52-week high at 19.97 USD", "summary": "Relay Therapeutics stock recently hit a 52-week high of $19.97, reflecting a significant return of 432% over the past year and substantial gains year-to-date. This surge is supported by positive analyst ratings and recent plans to raise $450 million through stock offerings, indic", "url": "https://www.investing.com/news/company-news/relay-therapeutics-stock-hits-52week-high-at-1997-usd-93CH-4779693", "source_name": "Investing.com", "published_at": "2026-07-07T15:41:45", "published_display": "07 Jul 2026 15:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics stock hits 52-week high at 19.97 USD By Investing.com", "summary": "Relay Therapeutics (RLAY) stock reached a new 52-week high of $19.97, reflecting a significant year-over-year return of 432%. Despite this surge, InvestingPro suggests the company may be overvalued relative to its Fair Value. The biotech company recently announced a $275 million ", "url": "https://ca.investing.com/news/stock-market-news/relay-therapeutics-stock-hits-52week-high-at-1997-usd-93CH-4723541", "source_name": "Investing.com Canada", "published_at": "2026-07-07T14:40:28", "published_display": "07 Jul 2026 14:40", "sentiment": "positive", "sentiment_pct": 80, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Relay Therapeutics, Inc. \u2013 NASDAQ:RLAY", "summary": "The article provides a financial metric\u2014enterprise value to revenue forward\u2014for Relay Therapeutics, Inc., traded on NASDAQ under the symbol RLAY. It appears to be a stub or a data point from a financial platform, indicating a value without additional surrounding context or detail", "url": "https://www.tradingview.com/symbols/NASDAQ-RLAY/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T12:40:28", "published_display": "07 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Relay Therapeutics, Inc. \u2013 NASDAQ:RLAY", "summary": "This article provides financial information for Relay Therapeutics, Inc. (NASDAQ: RLAY), focusing on its forward price-to-sales ratio. It presents various financial data points and market information related to the company on the TradingView platform. The content is brief, primar", "url": "https://www.tradingview.com/symbols/NASDAQ-RLAY/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T01:12:03", "published_display": "07 Jul 2026 01:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Relay Therapeutics, Inc. \u2013 NASDAQ:RLAY", "summary": "This article provides financial performance data for Relay Therapeutics, Inc. (NASDAQ: RLAY), specifically focusing on its forward price-to-book ratio. The content is hosted on TradingView, an investment analysis platform, indicating that the information is intended for investors", "url": "https://www.tradingview.com/symbols/NASDAQ-RLAY/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T16:09:50", "published_display": "03 Jul 2026 16:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Peter Rahmer Sells 50,000 Shares of Relay Therapeu", "summary": "Peter Rahmer, an insider at Relay Therapeutics Inc (RLAY), sold 50,000 shares on June 30, 2026, and now holds 228,913 shares. Over the past year, Rahmer has sold 121,403 shares with no purchases, part of a company-wide trend of 22 insider sells and no buys. Shares traded at $19.0", "url": "https://www.gurufocus.com/news/8943777/insider-sell-peter-rahmer-sells-50000-shares-of-relay-therapeutics-inc-rlay", "source_name": "GuruFocus", "published_at": "2026-07-03T05:40:23", "published_display": "03 Jul 2026 05:40", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics (RLAY) exec ESPP buy, 50K-share 10b5-1 sale", "summary": "Peter Rahmer, an executive at Relay Therapeutics (RLAY), reported both a sale and an acquisition of company stock on June 30, 2026. He sold 50,000 shares at a weighted average price of $19.09 under a pre-arranged Rule 10b5-1 trading plan and simultaneously acquired 3,056 shares a", "url": "https://www.stocktitan.net/sec-filings/RLAY/form-4-relay-therapeutics-inc-insider-trading-activity-91b15a1f0821.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:40:23", "published_display": "02 Jul 2026 20:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RLAY (NASDAQ: RLAY) Form 144: 50,000 Performance Stock Units; 753-share sale", "summary": "A Form 144 filing for Relay Therapeutics (RLAY) reports the intent related to 50,000 Performance Stock Units (PSUs) dated January 29, 2025, and discloses a recent sale of 753 common shares on April 28, 2026, for $11,136.87. The filing is considered routine and administrative, pro", "url": "https://www.stocktitan.net/sec-filings/RLAY/144-relay-therapeutics-inc-sec-filing-90157d62ed42.html", "source_name": "Stock Titan", "published_at": "2026-07-01T04:40:53", "published_display": "01 Jul 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics (RLAY) Joins Multiple Russell Growth Indexes Is Its Biotech Role Being Repriced?", "summary": "Relay Therapeutics (RLAY) has been added to several Russell growth indexes including the Russell 3000 Growth and Russell 2000 Growth. While this inclusion could increase visibility and liquidity, it doesn't alter the core investment narrative which is still centered on clinical p", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rlay/relay-therapeutics/news/relay-therapeutics-rlay-joins-multiple-russell-growth-indexe", "source_name": "Simply Wall Street", "published_at": "2026-07-01T04:40:53", "published_display": "01 Jul 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics Insider Sale Tops $3 Million as Shares Surge 500% This Past Year", "summary": "Relay Therapeutics CFO Thomas Catinazzo sold over $3 million in company stock after exercising options, a move explained by a Rule 10b5-1 trading plan and not a shift in strategy. Despite the sale, Catinazzo retains significant equity exposure through unexercised options. The com", "url": "https://finance.yahoo.com/markets/stocks/articles/relay-therapeutics-insider-sale-tops-001202900.html", "source_name": "Market source", "published_at": "2026-06-30T00:39:30", "published_display": "30 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics, Inc.(NasdaqGM:RLAY) added to Russell Small Cap Comp Growth Benchmark", "summary": "Relay Therapeutics, Inc. (NasdaqGM:RLAY) has been added to the Russell Small Cap Comp Growth Benchmark. This inclusion is significant for the clinical-stage biotechnology company, which focuses on developing small molecule precision medicines for cancer and genetic diseases using", "url": "https://www.marketscreener.com/news/relay-therapeutics-inc-nasdaqgm-rlay-added-to-russell-small-cap-comp-growth-benchmark-ce7f5fdfdc88f220", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T21:39:30", "published_display": "29 Jun 2026 21:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is RLAY Stock Rising Today?", "summary": "Relay Therapeutics (RLAY) shares surged by 10% in pre-market trading after announcing positive early-stage clinical data for Zovegalisib, its experimental treatment for vascular anomalies. The study showed strong efficacy with 60% of evaluable patients achieving significant lesio", "url": "https://stocktwits.com/news-articles/markets/equity/why-is-rlay-stock-rising-today/cZXuoXhReZq", "source_name": "Stocktwits", "published_at": "2026-06-26T16:40:35", "published_display": "26 Jun 2026 16:40", "sentiment": "positive", "sentiment_pct": 94, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics, Inc. Actuals & Estimates (NASDAQ:RLAY)", "summary": "This article provides an overview of Relay Therapeutics, Inc. (NASDAQ: RLAY) stock performance, forecasts, and financial data. It details the current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings report. The piece also includes a", "url": "https://www.tradingview.com/symbols/NASDAQ-RLAY/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T15:09:16", "published_display": "26 Jun 2026 15:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics (RLAY) Short Interest & Short Float | Updated Jun 2026 $RLAY", "summary": "As of June 15, 2026, Relay Therapeutics (RLAY) had a short interest of 38.12 million shares, representing 20.96% of its public float, marking a 10.86% increase from the prior report. The short interest ratio is 9.9 days to cover. This data indicates a significant bearish sentimen", "url": "https://www.marketbeat.com/stocks/NASDAQ/RLAY/short-interest/", "source_name": "MarketBeat", "published_at": "2026-06-26T03:40:12", "published_display": "26 Jun 2026 03:40", "sentiment": "negative", "sentiment_pct": 33, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RLAY Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "Relay Therapeutics, Inc. (RLAY) stock has seen significant growth, rising 465.34% over the last year. Analysts have provided price forecasts for RLAY, with a maximum estimate of $32.00 and a minimum of $20.00. The company is set to release its next earnings report on August 6, 20", "url": "https://www.tradingview.com/symbols/NASDAQ-RLAY/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T03:39:55", "published_display": "26 Jun 2026 03:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics Stock Rockets 34% With 9-Day Winning Streak", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOSFRrYUlzeTNrYWgzMnBUaDlZeVFhT2tTZElaTXhVZ3hjamVqTzZOZEV5dk5KQWJ3YS03Yy1tZ0U0cVRrQThQbzRTV3A4eXZXRVEwSGp0TDVBLTFVSWtfdmUteldrZHNRU2pEUkh4WjJrc3Y3RW0tbGs4dGNjck00bFAxdW1TOWI1clhFZVI5QUZ3Z09jNlRHQkxZcndPM0Q1Ri0yblhRWkNJQzhKY1o5QXptMmRVeG1EMlU2WE4xSQ?oc=5", "source_name": "Trefis", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics Insider Sold Shares Worth $1,583,145, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/relay-therapeutics-insider-sold-shares-201239783.html", "source_name": "MT Newswires", "published_at": "2026-06-24T20:12:39+00:00", "published_display": "24 Jun 2026 20:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics (RLAY) R&D chief exercises options and sells 93K shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxONWxoU0JCX1pCVEpwY05XVGUzdDB6a3VBN2s5aHRJNHNTVklMVXl5MjZlX2hreURWMldYbkJKcUhwd2dVM1cxR2NFdFJTSUlpNHAwdko0bHNaTzRmemw4UmNjM0s2N1hWNVc0S2U0Sno0U1owMzhxVjhzemE2dXhrcTJSRkRtZTlqUDhDM3BLUVJRSXhhNkxkaS00b2ZvblNFZUlWV2NLa2NoLUR6WmJQOVZleHVVQ2s?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "8-Day Rally Sends Relay Therapeutics Stock Up 29%", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOS2hNbEZTTkhNeUh3Z0xpMzFsRWcwVHRUdDRJYWRIcHgxTkNNZmVrTmFuLUw0UlF3UFBZSU5lVWQydWpsZWhTNEZPdG1nZXUwTEdyei1XV0p6SzRRTktzMHZPSWRiejNaTWNrdE4tVFpfYXcxc042RmRqS0FzQTN3OTdTUkJ4VkYzRTBRc1hCaXZPNzZkc0JwQndJdzl6WlJVLTgwU3hLQjVWWTF6cFMwZ2t5LWZLdVJrMnVR?oc=5", "source_name": "Trefis", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Top Smidcap Pick: TD Cowen Highlights Relay Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPNGYwSDlmS29WZzZoWG03Q0RqTVJfT1dHMmVNbk1rallGMmtaYUcwLVdRN3F1dV9sRlJjc3JzM3NWNFNkRTJGTHo4YlEzM3lHZ1BxWlNoM0xMRFpfbW1fZGFMUGh1aDFJci0zVlBKYmt4S1l2R0c2eEdyVzMxV3BDT0lUOUVJZFJNYUVGWGpMcnl2UzRwYVZoQlBWNzgtenpEclJzRjhxUDBkZC1FNTlMcVBlbXhubm9l?oc=5", "source_name": "Investing.com", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics (RLAY) Stock Valuation After Analyst Upgrades On Early Zovegalisib Data", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-14T07:00:00+00:00", "published_display": "14 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics (RLAY) is One of the Best AI Driven Biotech Stocks, Here is Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNU3h2OXBrU2Y2QktqYmhBT2NnUEJQajJmbDE0dEpPN3ZaTDQxVTNoTjVNSG0wc01yamtfM2xPNVhuQWNWT2pWaGdNclZvYjJpTEpYZmJKUEN5YWFTZE16U2VvVVdUU3lCc2o0SGo1OW5HdmlXT1l0VnAzVGV2MEN3SkdRbFFJWEpzN2o1eURSLUNSOFBMVjhpT0Q1RW5sQUl4OWpN?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/relay-therapeutics-participate-two-upcoming-200500865.html", "source_name": "GlobeNewswire", "published_at": "2026-05-27T20:05:00+00:00", "published_display": "27 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Relay Therapeutics a Buy After Promising Trial Results?", "summary": "", "url": "https://finance.yahoo.com/m/e9667424-d596-37fb-a6db-ba4439ee991a/is-relay-therapeutics-a-buy.html", "source_name": "Motley Fool", "published_at": "2026-05-22T21:50:00+00:00", "published_display": "22 May 2026 21:50", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics (RLAY) Is Up 6.9% After Follow-On Offering And Early Zovegalisib Data Release", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/relay-therapeutics-rlay-6-9-021606867.html", "source_name": "Simply Wall St.", "published_at": "2026-05-22T02:16:06+00:00", "published_display": "22 May 2026 02:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics Prices Underwritten Public Offering of Common Stock Raising Approximately $275 Million", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxQQkl2d1dsTUkwTFdfSUh4MDZQTzNjajRxVEpIamNocV9rNi11WkZld2F1WFZxNGd3QkFkdHFKQmtuOFhsMUNGbjB0XzJQN05NbWJtWl9JaHduYnNHN3VkYWM3TkhuMG90dDVrdjMwMXVGVG9FY0pBR1pVVkVJOWNmRE42V2xVWVQtYXhsaVQxZVJRb3l4WWhqemtFa2I2TzVCYzQ4bjVkWUIzYlNGX1dkSmNXbTNENk40eGc1YS1FYm9HbW1EYmRacDVpbTRnbHl0OVo2Smc0dw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics Stock Rises on Promising Clinical Data and Analyst Upgrades", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNVzRxd2FNTEQwYms3VWxYM2prblF2cGMyVjhQLXpNY2RIQkpLeEh6YTlHX19KWE9ZUVhOWTNRUDZoTWRXT2tGRl9TZkVEWHMwZ2M2NjZFRmtkakcyOGZvR0hhMGpXTXR4UlIyUVBCRjJnTDVQNWF0X2JKM1J3bnEzS3d5S0VuZkpNYlhqVXBXVHMxZ21DOTBEeWZibEhvOUxkbldtSklUNzVmOFFo?oc=5", "source_name": "IndexBox", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics Announces Pricing of Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxOdUxsUHBJVUwyemxLMWJMSTlyd01PRnVTZ3cxMnc5T1JyMlRkZkxldjh1RGdJOW9TaS1fanIzMjhqaDRkNjYyWldhQmtrdHNBX29uR0ZHWVI1Q01pNFZRNXN3RlZ0M0RjcjhiZ2ZDek5WVnhRcWk3Tl93bnJuWjlRc1RWelFCeURFZTh1a1ZEV1BoR2x6SnRvTEl4YWtOZWpyNGJ3ZDVldHJ6TWdpbjhNWHdnZUFENF8zZmRkX0N2cWowYVdXZXJ0SmVpTTlkSUhlQnFiajVuWWV0NUk?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Relay Therapeutics Stock Popped on Wednesday", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNRmhyb05nZkRmQnFiOXNKMkh0dlVkRHZFOGlXOWlKQ1ViTHFPSGZlUFZ6dnAzaldRNVp6ellFS1NsZHJGRG94X0hsR1ZwVHhvWVpmaXB0RU1IcWJyT3lkUHg4bFNlUGItNVFycDFGSUhvWTl1ejdyaFhQQ1JpVWFKRGZQQmFxQVFKdlMyZzBoUE8xVlVoaFE?oc=5", "source_name": "The Motley Fool", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Relay Therapeutics (RLAY) Q1 Loss Of US$73.3 Million Tests Growth At A Loss Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxQcFdDWDQ0Y3VPRjJCam5RbTJjc0haQnZiakMtUjhjb19hY1E1S3RSVS1ydlB2UWVTaGN6RUNUZWNweHFaaXBQb2tKR05yVDBwVktLd2FZOHZ3Yzlzdk5vVzM1eUdFLVdyanVnaG9iSHhtTE1hRjV5clJCOEVvb0M2NlZLZUliN1NaaGFPUXAzd21lT013WHhyMlBjdWpKQlZzSUNWajF2TUxOQUx5WV9MYkt0RDRlX2FMdnY5bm5OSzJRTnpxZmRGalFhaVpmZUF3UmlVOWF4cEVFSUZwaEFGczF2dnQyU0dZd0RUeUFR?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNZzNaa3hHWlFzejdYeXd6QXhjNG01TXdEajkyMk5QVmRHTnM1cGNzWDNEcW0xNGVZYk16c0F6bUNmNzg0NDZQYVEteExJMWVFb1ZDWm1VaVNNcjJvUEl1UnhhUmlMZVpHUjN3Z2lfSHdqUmdybHhmM3lFLXFGdG80QmFZLTdvV2dKbWZVUTE0UTRtdnl1YzItU1FfVDR2akxfM3RoS0oxZw?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Are Betting On Relay Therapeutics, Inc. (NASDAQ:RLAY) With A Big Upgrade This Week", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics Call Puts Zovegalisib Breast Cancer Prospects In Focus", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics (RLAY) Falls Hard on Profit-Taking From 74% April Jump", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQSXBwWkJGTS1DQVkzMnpsMVF6OG55YUFzbHByVzFjMFZzX0RIcy1VMGhkZ3lmMW1Ca1NBMUxkUGN3TTNhRUZkNHFDZFpNMHNIeHRMRjNRekFqazMwNGVTam45OWJBQVdKWGZnbk1jbnR5c2tMQkVKYlk3Yzd6N3NYbjdsa3hPdU1Fb2c5cGFCQXhqejhYSWdyZmZ5bk5naHFw?oc=5", "source_name": "Market source", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "by_tier": {"direct": [{"title": "Canaccord initiates Relay Therapeutics stock with buy rating", "summary": "Canaccord has initiated coverage on Relay Therapeutics Inc. (NASDAQ:RLAY) with a buy rating and a price target of $29.00, citing its lead asset zovegalisib. The firm believes zovegalisib, targeting mutant PI3K\u03b1, offers improved efficacy and safety for breast cancer and vascular a", "url": "https://www.investing.com/news/analyst-ratings/canaccord-initiates-relay-therapeutics-stock-with-buy-rating-93CH-4796138", "source_name": "Investing.com", "published_at": "2026-07-16T14:11:07", "published_display": "16 Jul 2026 14:11", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Canaccord Genuity Initiates Relay Therapeutics at Buy With $29 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/canaccord-genuity-initiates-relay-therapeutics-113810107.html", "source_name": "MT Newswires", "published_at": "2026-07-16T11:38:10+00:00", "published_display": "16 Jul 2026 11:38", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CCORF Initiates Relay Therapeutics(RLAY.US) With Buy Rating, Announces Target Price $29", "summary": "CCORF has initiated coverage on Relay Therapeutics (RLAY.US) with a \"Buy\" rating. The firm has set a target price of $29 for the company's shares. This indicates a positive outlook on Relay Therapeutics' future performance by CCORF.", "url": "https://www.moomoo.com/news/post/73067634/ccorf-initiates-relay-therapeutics-rlayus-with-buy-rating-announces-target", "source_name": "Moomoo", "published_at": "2026-07-16T10:11:07", "published_display": "16 Jul 2026 10:11", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RLAY Stock Declines Pre-Market After $175M Offering \u2014 Despite Fresh Bullish Calls On Relay's Zovegalisib", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxNTTRWSldfYzZKOVR1LWFXbUl6YklEa0l5UmJlX2VhekVkV2hqQmxUR1VCNXBlZEV2QUIyYjRRQm9Gcy1tWUFMc1VhWFhHQXVmYWd3MTdSbWxOMGY3STZWQkpsdWhnejJKSURlR0R1MHJsQjV0Wmo3el9oWGZnMDM0LXN1T2lCdGR6Zl9WOUg3TnVaMWVHaGE3YnpOcmdXTmQ5WjJJTkhxcDdsX0thZF9SRko4NDlIcmtfU2pmUElIXzJYSVNyV2JyQmRIWWhJSEZMMjJCWA?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-14T15:18:41+00:00", "published_display": "14 Jul 2026 15:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Relay Therapeutics, Inc. \u2013 NASDAQ:RLAY", "summary": "This article provides a financial overview of Relay Therapeutics, Inc. (NASDAQ: RLAY), focusing on its forward price-to-earnings ratio. It presents the company's financial data as available on TradingView, indicating that the market was closed at the time of publication with no t", "url": "https://www.tradingview.com/symbols/NASDAQ-RLAY/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T10:10:15", "published_display": "09 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics Insider Sold Shares Worth $331,131, According to a Recent SEC Filing", "summary": "A recent SEC filing revealed that Richard Peters, Chief Executive Officer of Relay Therapeutics, sold 30,000 shares of the company's common stock for a total of $331,131. The sale occurred at an average price of $11.0377 per share. Following this transaction, Peters still directl", "url": "https://www.moomoo.com/news/post/72670469/relay-therapeutics-insider-sold-shares-worth-331131-according-to-a", "source_name": "Moomoo", "published_at": "2026-07-09T02:10:57", "published_display": "09 Jul 2026 02:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell Alert: Donald Bergstrom Sells Shares of Relay Thera", "summary": "Donald Bergstrom, President of Research and Development at Relay Therapeutics Inc (RLAY), recently sold 8,660 company shares, reducing his holdings to 409,897 shares. This transaction is part of a trend over the last year where Bergstrom has sold 186,854 shares with no purchases,", "url": "https://www.gurufocus.com/news/8950625/insider-sell-alert-donald-bergstrom-sells-shares-of-relay-therapeutics-inc-rlay", "source_name": "GuruFocus", "published_at": "2026-07-09T01:10:57", "published_display": "09 Jul 2026 01:10", "sentiment": "negative", "sentiment_pct": 26, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics Insider Sold Shares Worth $943,736, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/relay-therapeutics-insider-sold-shares-211220901.html", "source_name": "MT Newswires", "published_at": "2026-07-08T21:12:20+00:00", "published_display": "08 Jul 2026 21:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics (RLAY) R&D chief sells 8,660 shares in 10b5-1 trade", "summary": "Donald A. Bergstrom, President of R&D at Relay Therapeutics (RLAY), sold 8,660 shares of common stock at a weighted average price of $18.71 per share under a pre-arranged Rule 10b5-1 trading plan. After the sale, Bergstrom still directly holds 409,897 shares, including restricted", "url": "https://www.stocktitan.net/sec-filings/RLAY/form-4-relay-therapeutics-inc-insider-trading-activity-c0d19af0a5f3.html", "source_name": "Stock Titan", "published_at": "2026-07-08T22:10:57", "published_display": "08 Jul 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics president and CEO Sanjiv Patel sells $943,736 in stock", "summary": "Sanjiv Patel, President and CEO of Relay Therapeutics (NASDAQ:RLAY), sold $943,736 worth of company stock on July 7, 2026, as part of a pre-arranged trading plan. This sale occurred while the stock was trading near its 52-week high, following a significant 450% gain over the past", "url": "https://www.investing.com/news/insider-trading-news/relay-therapeutics-president-and-ceo-sanjiv-patel-sells-943736-in-stock-93CH-4782624", "source_name": "Investing.com", "published_at": "2026-07-08T21:10:57", "published_display": "08 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics CFO Thomas Catinazzo sells $331,130 in stock", "summary": "Relay Therapeutics CFO Thomas Catinazzo sold 17,717 shares of the company's common stock for a total of $331,130 on July 6, 2026. The sale was executed via a Rule 10b5-1 trading plan and occurred while the stock (NASDAQ: RLAY) traded near its 52-week high after a significant gain", "url": "https://www.investing.com/news/insider-trading-news/relay-therapeutics-cfo-thomas-catinazzo-sells-331130-in-stock-93CH-4782587", "source_name": "Investing.com", "published_at": "2026-07-08T21:10:57", "published_display": "08 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics president sells $162,028 in company stock", "summary": "Donald A. Bergstrom, President, R&D at Relay Therapeutics (NASDAQ:RLAY), sold 8,660 shares of company stock for $162,028 on July 6, 2026, through a pre-arranged trading plan. This transaction occurred while Relay shares are near their 52-week high, following significant gains. De", "url": "https://www.investing.com/news/insider-trading-news/relay-therapeutics-president-sells-162028-in-company-stock-93CH-4782609", "source_name": "Investing.com", "published_at": "2026-07-08T21:10:57", "published_display": "08 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CFO at Relay Therapeutics (RLAY) sells shares under Rule 10b5-1 plan", "summary": "Relay Therapeutics CFO Thomas Catinazzo sold 17,717 shares of common stock on July 6, 2026, generating $331,131 at a weighted average price of $18.69 per share. These transactions were pre-arranged under a Rule 10b5-1 trading plan adopted in October 2025. Following the sale, Cati", "url": "https://www.stocktitan.net/sec-filings/RLAY/form-4-relay-therapeutics-inc-insider-trading-activity-5b084534580b.html", "source_name": "Stock Titan", "published_at": "2026-07-08T21:10:57", "published_display": "08 Jul 2026 21:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics (RLAY) CEO trades shares, keeps over 615K direct holdings", "summary": "Relay Therapeutics President and CEO Sanjiv Patel reported selling 48,199 shares of common stock at a weighted average price of $19.58 under a pre-established 10b5-1 trading plan. This transaction followed an acquisition of 3,056 shares through the company's Employee Stock Purcha", "url": "https://www.stocktitan.net/sec-filings/RLAY/form-4-relay-therapeutics-inc-insider-trading-activity-337e491872ee.html", "source_name": "Stock Titan", "published_at": "2026-07-08T21:10:57", "published_display": "08 Jul 2026 21:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Relay Therapeutics (RLAY) Is Up 5.5% After Broad Russell Growth Index Inclusion And What's Next", "summary": "Relay Therapeutics (RLAY) was included in multiple Russell Growth and Small Cap indices in late June 2026, boosting its visibility among institutional investors. While this inclusion may deepen liquidity and expand its shareholder base, it does not change the fundamental risks as", "url": "https://www.sahmcapital.com/news/content/why-relay-therapeutics-rlay-is-up-55-after-broad-russell-growth-index-inclusion-and-whats-next-2026-07-08", "source_name": "Sahm", "published_at": "2026-07-08T21:09:17", "published_display": "08 Jul 2026 21:09", "sentiment": "positive", "sentiment_pct": 60, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan initiates Relay Therapeutics stock coverage with overweight rating", "summary": "JPMorgan has initiated coverage on Relay Therapeutics Inc. (NASDAQ:RLAY) with an overweight rating and a $28 price target, citing its drug zovegalisib as a potential multi-indication growth driver with projected worldwide peak sales of approximately $8.3 billion. The stock, curre", "url": "https://www.investing.com/news/analyst-ratings/jpmorgan-initiates-relay-therapeutics-stock-coverage-with-overweight-rating-93CH-4780785", "source_name": "Investing.com", "published_at": "2026-07-08T08:09:31", "published_display": "08 Jul 2026 08:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 RELAY THERAPEUTICS INC For: 7 July By Investing.com", "summary": "This article announces the filing of Form 144 for RELAY THERAPEUTICS INC on July 7. The filing is a standard requirement for insiders wishing to sell restricted or control securities. This brief update is relevant for investors tracking insider transactions and regulatory filings", "url": "https://ca.investing.com/news/stock-market-news/form-144-relay-therapeutics-inc-for-7-july-93CH-4724062", "source_name": "Investing.com Canada", "published_at": "2026-07-07T21:41:45", "published_display": "07 Jul 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Relay Therapeutics, Inc. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPUXp1VXJOWnlmWmNxaFJkNHJ3U3RNR09kTHZrd0VGWk9oMDFhTWdIekp2S2Nlb3g0bGp5d29jeWZRVlpHQnE2MGo5bEVGUmJUcGNDemx3Nkg0LWY5dmtjSi1FZXljUXNZMUpPTWxjNXRPbU43UzNEb3V1aTViM2RSWFZNdWdmUFhpYlpWd2RXM0hGZzd1c3VuUWFCMDBzMGx3?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-07T20:37:03+00:00", "published_display": "07 Jul 2026 20:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics stock hits 52-week high at 19.97 USD", "summary": "Relay Therapeutics stock recently hit a 52-week high of $19.97, reflecting a significant return of 432% over the past year and substantial gains year-to-date. This surge is supported by positive analyst ratings and recent plans to raise $450 million through stock offerings, indic", "url": "https://www.investing.com/news/company-news/relay-therapeutics-stock-hits-52week-high-at-1997-usd-93CH-4779693", "source_name": "Investing.com", "published_at": "2026-07-07T15:41:45", "published_display": "07 Jul 2026 15:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics stock hits 52-week high at 19.97 USD By Investing.com", "summary": "Relay Therapeutics (RLAY) stock reached a new 52-week high of $19.97, reflecting a significant year-over-year return of 432%. Despite this surge, InvestingPro suggests the company may be overvalued relative to its Fair Value. The biotech company recently announced a $275 million ", "url": "https://ca.investing.com/news/stock-market-news/relay-therapeutics-stock-hits-52week-high-at-1997-usd-93CH-4723541", "source_name": "Investing.com Canada", "published_at": "2026-07-07T14:40:28", "published_display": "07 Jul 2026 14:40", "sentiment": "positive", "sentiment_pct": 80, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Relay Therapeutics, Inc. \u2013 NASDAQ:RLAY", "summary": "The article provides a financial metric\u2014enterprise value to revenue forward\u2014for Relay Therapeutics, Inc., traded on NASDAQ under the symbol RLAY. It appears to be a stub or a data point from a financial platform, indicating a value without additional surrounding context or detail", "url": "https://www.tradingview.com/symbols/NASDAQ-RLAY/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T12:40:28", "published_display": "07 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Relay Therapeutics, Inc. \u2013 NASDAQ:RLAY", "summary": "This article provides financial information for Relay Therapeutics, Inc. (NASDAQ: RLAY), focusing on its forward price-to-sales ratio. It presents various financial data points and market information related to the company on the TradingView platform. The content is brief, primar", "url": "https://www.tradingview.com/symbols/NASDAQ-RLAY/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T01:12:03", "published_display": "07 Jul 2026 01:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Relay Therapeutics, Inc. \u2013 NASDAQ:RLAY", "summary": "This article provides financial performance data for Relay Therapeutics, Inc. (NASDAQ: RLAY), specifically focusing on its forward price-to-book ratio. The content is hosted on TradingView, an investment analysis platform, indicating that the information is intended for investors", "url": "https://www.tradingview.com/symbols/NASDAQ-RLAY/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T16:09:50", "published_display": "03 Jul 2026 16:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Peter Rahmer Sells 50,000 Shares of Relay Therapeu", "summary": "Peter Rahmer, an insider at Relay Therapeutics Inc (RLAY), sold 50,000 shares on June 30, 2026, and now holds 228,913 shares. Over the past year, Rahmer has sold 121,403 shares with no purchases, part of a company-wide trend of 22 insider sells and no buys. Shares traded at $19.0", "url": "https://www.gurufocus.com/news/8943777/insider-sell-peter-rahmer-sells-50000-shares-of-relay-therapeutics-inc-rlay", "source_name": "GuruFocus", "published_at": "2026-07-03T05:40:23", "published_display": "03 Jul 2026 05:40", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics (RLAY) exec ESPP buy, 50K-share 10b5-1 sale", "summary": "Peter Rahmer, an executive at Relay Therapeutics (RLAY), reported both a sale and an acquisition of company stock on June 30, 2026. He sold 50,000 shares at a weighted average price of $19.09 under a pre-arranged Rule 10b5-1 trading plan and simultaneously acquired 3,056 shares a", "url": "https://www.stocktitan.net/sec-filings/RLAY/form-4-relay-therapeutics-inc-insider-trading-activity-91b15a1f0821.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:40:23", "published_display": "02 Jul 2026 20:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RLAY (NASDAQ: RLAY) Form 144: 50,000 Performance Stock Units; 753-share sale", "summary": "A Form 144 filing for Relay Therapeutics (RLAY) reports the intent related to 50,000 Performance Stock Units (PSUs) dated January 29, 2025, and discloses a recent sale of 753 common shares on April 28, 2026, for $11,136.87. The filing is considered routine and administrative, pro", "url": "https://www.stocktitan.net/sec-filings/RLAY/144-relay-therapeutics-inc-sec-filing-90157d62ed42.html", "source_name": "Stock Titan", "published_at": "2026-07-01T04:40:53", "published_display": "01 Jul 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics (RLAY) Joins Multiple Russell Growth Indexes Is Its Biotech Role Being Repriced?", "summary": "Relay Therapeutics (RLAY) has been added to several Russell growth indexes including the Russell 3000 Growth and Russell 2000 Growth. While this inclusion could increase visibility and liquidity, it doesn't alter the core investment narrative which is still centered on clinical p", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rlay/relay-therapeutics/news/relay-therapeutics-rlay-joins-multiple-russell-growth-indexe", "source_name": "Simply Wall Street", "published_at": "2026-07-01T04:40:53", "published_display": "01 Jul 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics Insider Sale Tops $3 Million as Shares Surge 500% This Past Year", "summary": "Relay Therapeutics CFO Thomas Catinazzo sold over $3 million in company stock after exercising options, a move explained by a Rule 10b5-1 trading plan and not a shift in strategy. Despite the sale, Catinazzo retains significant equity exposure through unexercised options. The com", "url": "https://finance.yahoo.com/markets/stocks/articles/relay-therapeutics-insider-sale-tops-001202900.html", "source_name": "Market source", "published_at": "2026-06-30T00:39:30", "published_display": "30 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics, Inc.(NasdaqGM:RLAY) added to Russell Small Cap Comp Growth Benchmark", "summary": "Relay Therapeutics, Inc. (NasdaqGM:RLAY) has been added to the Russell Small Cap Comp Growth Benchmark. This inclusion is significant for the clinical-stage biotechnology company, which focuses on developing small molecule precision medicines for cancer and genetic diseases using", "url": "https://www.marketscreener.com/news/relay-therapeutics-inc-nasdaqgm-rlay-added-to-russell-small-cap-comp-growth-benchmark-ce7f5fdfdc88f220", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T21:39:30", "published_display": "29 Jun 2026 21:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is RLAY Stock Rising Today?", "summary": "Relay Therapeutics (RLAY) shares surged by 10% in pre-market trading after announcing positive early-stage clinical data for Zovegalisib, its experimental treatment for vascular anomalies. The study showed strong efficacy with 60% of evaluable patients achieving significant lesio", "url": "https://stocktwits.com/news-articles/markets/equity/why-is-rlay-stock-rising-today/cZXuoXhReZq", "source_name": "Stocktwits", "published_at": "2026-06-26T16:40:35", "published_display": "26 Jun 2026 16:40", "sentiment": "positive", "sentiment_pct": 94, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics, Inc. Actuals & Estimates (NASDAQ:RLAY)", "summary": "This article provides an overview of Relay Therapeutics, Inc. (NASDAQ: RLAY) stock performance, forecasts, and financial data. It details the current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings report. The piece also includes a", "url": "https://www.tradingview.com/symbols/NASDAQ-RLAY/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T15:09:16", "published_display": "26 Jun 2026 15:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics (RLAY) Short Interest & Short Float | Updated Jun 2026 $RLAY", "summary": "As of June 15, 2026, Relay Therapeutics (RLAY) had a short interest of 38.12 million shares, representing 20.96% of its public float, marking a 10.86% increase from the prior report. The short interest ratio is 9.9 days to cover. This data indicates a significant bearish sentimen", "url": "https://www.marketbeat.com/stocks/NASDAQ/RLAY/short-interest/", "source_name": "MarketBeat", "published_at": "2026-06-26T03:40:12", "published_display": "26 Jun 2026 03:40", "sentiment": "negative", "sentiment_pct": 33, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RLAY Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "Relay Therapeutics, Inc. (RLAY) stock has seen significant growth, rising 465.34% over the last year. Analysts have provided price forecasts for RLAY, with a maximum estimate of $32.00 and a minimum of $20.00. The company is set to release its next earnings report on August 6, 20", "url": "https://www.tradingview.com/symbols/NASDAQ-RLAY/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T03:39:55", "published_display": "26 Jun 2026 03:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics Stock Rockets 34% With 9-Day Winning Streak", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOSFRrYUlzeTNrYWgzMnBUaDlZeVFhT2tTZElaTXhVZ3hjamVqTzZOZEV5dk5KQWJ3YS03Yy1tZ0U0cVRrQThQbzRTV3A4eXZXRVEwSGp0TDVBLTFVSWtfdmUteldrZHNRU2pEUkh4WjJrc3Y3RW0tbGs4dGNjck00bFAxdW1TOWI1clhFZVI5QUZ3Z09jNlRHQkxZcndPM0Q1Ri0yblhRWkNJQzhKY1o5QXptMmRVeG1EMlU2WE4xSQ?oc=5", "source_name": "Trefis", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics Insider Sold Shares Worth $1,583,145, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/relay-therapeutics-insider-sold-shares-201239783.html", "source_name": "MT Newswires", "published_at": "2026-06-24T20:12:39+00:00", "published_display": "24 Jun 2026 20:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics (RLAY) R&D chief exercises options and sells 93K shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxONWxoU0JCX1pCVEpwY05XVGUzdDB6a3VBN2s5aHRJNHNTVklMVXl5MjZlX2hreURWMldYbkJKcUhwd2dVM1cxR2NFdFJTSUlpNHAwdko0bHNaTzRmemw4UmNjM0s2N1hWNVc0S2U0Sno0U1owMzhxVjhzemE2dXhrcTJSRkRtZTlqUDhDM3BLUVJRSXhhNkxkaS00b2ZvblNFZUlWV2NLa2NoLUR6WmJQOVZleHVVQ2s?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "8-Day Rally Sends Relay Therapeutics Stock Up 29%", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOS2hNbEZTTkhNeUh3Z0xpMzFsRWcwVHRUdDRJYWRIcHgxTkNNZmVrTmFuLUw0UlF3UFBZSU5lVWQydWpsZWhTNEZPdG1nZXUwTEdyei1XV0p6SzRRTktzMHZPSWRiejNaTWNrdE4tVFpfYXcxc042RmRqS0FzQTN3OTdTUkJ4VkYzRTBRc1hCaXZPNzZkc0JwQndJdzl6WlJVLTgwU3hLQjVWWTF6cFMwZ2t5LWZLdVJrMnVR?oc=5", "source_name": "Trefis", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Top Smidcap Pick: TD Cowen Highlights Relay Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPNGYwSDlmS29WZzZoWG03Q0RqTVJfT1dHMmVNbk1rallGMmtaYUcwLVdRN3F1dV9sRlJjc3JzM3NWNFNkRTJGTHo4YlEzM3lHZ1BxWlNoM0xMRFpfbW1fZGFMUGh1aDFJci0zVlBKYmt4S1l2R0c2eEdyVzMxV3BDT0lUOUVJZFJNYUVGWGpMcnl2UzRwYVZoQlBWNzgtenpEclJzRjhxUDBkZC1FNTlMcVBlbXhubm9l?oc=5", "source_name": "Investing.com", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics (RLAY) Stock Valuation After Analyst Upgrades On Early Zovegalisib Data", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-14T07:00:00+00:00", "published_display": "14 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics (RLAY) is One of the Best AI Driven Biotech Stocks, Here is Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNU3h2OXBrU2Y2QktqYmhBT2NnUEJQajJmbDE0dEpPN3ZaTDQxVTNoTjVNSG0wc01yamtfM2xPNVhuQWNWT2pWaGdNclZvYjJpTEpYZmJKUEN5YWFTZE16U2VvVVdUU3lCc2o0SGo1OW5HdmlXT1l0VnAzVGV2MEN3SkdRbFFJWEpzN2o1eURSLUNSOFBMVjhpT0Q1RW5sQUl4OWpN?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/relay-therapeutics-participate-two-upcoming-200500865.html", "source_name": "GlobeNewswire", "published_at": "2026-05-27T20:05:00+00:00", "published_display": "27 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Relay Therapeutics a Buy After Promising Trial Results?", "summary": "", "url": "https://finance.yahoo.com/m/e9667424-d596-37fb-a6db-ba4439ee991a/is-relay-therapeutics-a-buy.html", "source_name": "Motley Fool", "published_at": "2026-05-22T21:50:00+00:00", "published_display": "22 May 2026 21:50", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics (RLAY) Is Up 6.9% After Follow-On Offering And Early Zovegalisib Data Release", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/relay-therapeutics-rlay-6-9-021606867.html", "source_name": "Simply Wall St.", "published_at": "2026-05-22T02:16:06+00:00", "published_display": "22 May 2026 02:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics Prices Underwritten Public Offering of Common Stock Raising Approximately $275 Million", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxQQkl2d1dsTUkwTFdfSUh4MDZQTzNjajRxVEpIamNocV9rNi11WkZld2F1WFZxNGd3QkFkdHFKQmtuOFhsMUNGbjB0XzJQN05NbWJtWl9JaHduYnNHN3VkYWM3TkhuMG90dDVrdjMwMXVGVG9FY0pBR1pVVkVJOWNmRE42V2xVWVQtYXhsaVQxZVJRb3l4WWhqemtFa2I2TzVCYzQ4bjVkWUIzYlNGX1dkSmNXbTNENk40eGc1YS1FYm9HbW1EYmRacDVpbTRnbHl0OVo2Smc0dw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics Stock Rises on Promising Clinical Data and Analyst Upgrades", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNVzRxd2FNTEQwYms3VWxYM2prblF2cGMyVjhQLXpNY2RIQkpLeEh6YTlHX19KWE9ZUVhOWTNRUDZoTWRXT2tGRl9TZkVEWHMwZ2M2NjZFRmtkakcyOGZvR0hhMGpXTXR4UlIyUVBCRjJnTDVQNWF0X2JKM1J3bnEzS3d5S0VuZkpNYlhqVXBXVHMxZ21DOTBEeWZibEhvOUxkbldtSklUNzVmOFFo?oc=5", "source_name": "IndexBox", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics Announces Pricing of Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxOdUxsUHBJVUwyemxLMWJMSTlyd01PRnVTZ3cxMnc5T1JyMlRkZkxldjh1RGdJOW9TaS1fanIzMjhqaDRkNjYyWldhQmtrdHNBX29uR0ZHWVI1Q01pNFZRNXN3RlZ0M0RjcjhiZ2ZDek5WVnhRcWk3Tl93bnJuWjlRc1RWelFCeURFZTh1a1ZEV1BoR2x6SnRvTEl4YWtOZWpyNGJ3ZDVldHJ6TWdpbjhNWHdnZUFENF8zZmRkX0N2cWowYVdXZXJ0SmVpTTlkSUhlQnFiajVuWWV0NUk?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Relay Therapeutics Stock Popped on Wednesday", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNRmhyb05nZkRmQnFiOXNKMkh0dlVkRHZFOGlXOWlKQ1ViTHFPSGZlUFZ6dnAzaldRNVp6ellFS1NsZHJGRG94X0hsR1ZwVHhvWVpmaXB0RU1IcWJyT3lkUHg4bFNlUGItNVFycDFGSUhvWTl1ejdyaFhQQ1JpVWFKRGZQQmFxQVFKdlMyZzBoUE8xVlVoaFE?oc=5", "source_name": "The Motley Fool", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics (RLAY) Q1 Loss Of US$73.3 Million Tests Growth At A Loss Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxQcFdDWDQ0Y3VPRjJCam5RbTJjc0haQnZiakMtUjhjb19hY1E1S3RSVS1ydlB2UWVTaGN6RUNUZWNweHFaaXBQb2tKR05yVDBwVktLd2FZOHZ3Yzlzdk5vVzM1eUdFLVdyanVnaG9iSHhtTE1hRjV5clJCOEVvb0M2NlZLZUliN1NaaGFPUXAzd21lT013WHhyMlBjdWpKQlZzSUNWajF2TUxOQUx5WV9MYkt0RDRlX2FMdnY5bm5OSzJRTnpxZmRGalFhaVpmZUF3UmlVOWF4cEVFSUZwaEFGczF2dnQyU0dZd0RUeUFR?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNZzNaa3hHWlFzejdYeXd6QXhjNG01TXdEajkyMk5QVmRHTnM1cGNzWDNEcW0xNGVZYk16c0F6bUNmNzg0NDZQYVEteExJMWVFb1ZDWm1VaVNNcjJvUEl1UnhhUmlMZVpHUjN3Z2lfSHdqUmdybHhmM3lFLXFGdG80QmFZLTdvV2dKbWZVUTE0UTRtdnl1YzItU1FfVDR2akxfM3RoS0oxZw?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Are Betting On Relay Therapeutics, Inc. (NASDAQ:RLAY) With A Big Upgrade This Week", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics Call Puts Zovegalisib Breast Cancer Prospects In Focus", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Relay Therapeutics (RLAY) Falls Hard on Profit-Taking From 74% April Jump", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQSXBwWkJGTS1DQVkzMnpsMVF6OG55YUFzbHByVzFjMFZzX0RIcy1VMGhkZ3lmMW1Ca1NBMUxkUGN3TTNhRUZkNHFDZFpNMHNIeHRMRjNRekFqazMwNGVTam45OWJBQVdKWGZnbk1jbnR5c2tMQkVKYlk3Yzd6N3NYbjdsa3hPdU1Fb2c5cGFCQXhqejhYSWdyZmZ5bk5naHFw?oc=5", "source_name": "Market source", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 104, "total_relevant": 67, "sentiment_summary": {"positive": 16, "negative": 11, "neutral": 40, "score": 53, "total": 67, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 20.9, "count": 38}, {"event": "earnings", "label": "Earnings", "weight": 7.56, "count": 16}, {"event": "analyst", "label": "Analyst action", "weight": 4.4, "count": 8}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 16, "negative_events": 11}, "market_context": {"has_market_context": true, "latest_close": 20.0, "latest_week": "2026-07-10", "one_week_move": 7.3, "four_week_move": 35.1, "twelve_week_move": 19.4, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.830177, "market_dynamics_buy_signal": false, "relative_strength": 92.773443, "fair_value_gap": 164.8, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 59.4346, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+7.3% over one week, +35.1% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 62, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 9}, {"label": "Investing.com", "count": 7}, {"label": "Stock Titan", "count": 7}, {"label": "TradingView", "count": 6}, {"label": "simplywall.st", "count": 6}, {"label": "MT Newswires", "count": 3}, {"label": "GlobeNewswire", "count": 3}, {"label": "Moomoo", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 58}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 38}, {"label": "Earnings", "count": 16}, {"label": "Analyst action", "count": 8}, {"label": "Deals and strategy", "count": 2}, {"label": "Balance sheet", "count": 2}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "58", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+7.3% over one week, +35.1% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Canaccord initiates Relay Therapeutics stock with buy rating"}], "updated_at": "2026-07-18T04:16:15.783084+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}